BALPHARMA — Bal Pharma Income Statement
0.000.00%
- IN₹1.20bn
- IN₹2.64bn
- IN₹3.03bn
- 60
- 45
- 13
- 30
Annual income statement for Bal Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,505 | 2,812 | 3,042 | 3,392 | 3,031 |
| Cost of Revenue | |||||
| Gross Profit | 996 | 1,137 | 1,314 | 1,475 | 1,452 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2,356 | 2,668 | 2,882 | 3,178 | 2,833 |
| Operating Profit | 149 | 144 | 160 | 215 | 198 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 41 | 91.8 | 47.5 | 90.5 | 51.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 47.1 | 57 | 26.2 | 74.5 | 72.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 47.4 | 56.1 | 25.7 | 73.9 | 72.2 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 47.4 | 56.1 | 25.7 | 73.9 | 72.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 3.34 | 3.71 | 1.63 | 4.64 | 4.55 |
| Dividends per Share |